碘[^(131)I]美妥昔单抗注射液与肝动脉化疗栓塞术治疗原发性肝癌的对比研究  

A Comparative Study of Iodine[^(131)I]Metuximab Injection and Transcatheter Arterial Chemoembolization in the Treatment of Primary Liver Cancer

作　　者：郭恒照[1] 朱亚平[2] 毛延涛 王传玺[1] 房奇 韩俊庆[1] 丛林[5] 李强[1] 

机构地区：[1]山东大学附属省立医院肿瘤中心,济南250021 [2]广东医学院附属中山医院外科,中山528415 [3]山东省烟台山医院肿瘤科,烟台264000 [4]山东省肥城矿业中心医院消化科,肥城271608 [5]山东省医学影像学研究所,济南250021

出　　处：《成都医学院学报》2015年第6期649-651,656,共4页Journal of Chengdu Medical College

基　　金：山东省科技发展计划支持项目(No:2013YD18013);中国高校医学期刊临床专项资金(No:11521565)

摘　　要：目的对比分析碘[^(131)I]美妥昔单抗注射液与肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌(primary liver cancer,PLC)的临床疗效。方法根据治疗方法的不同将PLC患者分为TACE组(n=31)和碘[^(131)I]美妥昔单抗组(n=32)。TACE组行TACE治疗,碘[^(131)I]美妥昔单抗组经肝动脉途径灌注碘[^(131)I]美妥昔单抗注射液,治疗3个月后对两组甲胎蛋白(AFP)转阴率、肿瘤缩小率及生存期进行比较,并观察不良反应发生情况,随访至2015年8月。结果治疗3个月后,碘[^(131)I]美妥昔单抗组AFP转阴率及肿瘤缩小率略高于TACE组,但差异无统计学意义(P>0.05);治疗期间两组均无明显不良反应;截止到随访结束,TACE组生存率为19.4%(6/31),碘[^(131)I]美妥昔单抗组为43.8%(14/32),碘[^(131)I]美妥昔单抗组生存率高于TACE组,且差异有统计学意义(P<0.05)。结论对于PLC的治疗,碘[^(131)I]美妥昔单抗注射液在提高AFP转阴率、肿瘤缩小率及生存率方面优于TACE。Objective To compare the efficacy of Iodine[131^I]Metuximab Injection and transcatheter arterial chemoembolization（TACE）in the treatment of primary liver cancer（PLC）.Methods According to different treatment methods,the patients with PLC were divided into TACE group（n=31）and iodine[131^I]metuximab monoclonal antibody（mAb）group（n=32）.The patients in TACE group received TACE,while those in iodine[131^I]metuximab mAb group were perfused with Iodine[131^I]Metuximab Injection via hepatic artery.The rate of negative conversion of alpha fetoprotein（AFP）and tumor regression rate 3 months after treatment as well as survival rate were compared between two groups,and adverse reactions were observed closely.All patients were followed up until August,2015.Results 3 months after treatment,both negative conversion rate of AFP and tumor regression rate in iodine[131^I]metuximab mAb group were slightly higher than those in TACE group,but no statistically significant difference was presented（P〉0.05）.Until the end of follow-up,the survival rate of TACE group was 19.4%（6/31）,which was markedly lower than the 43.8%（14/32）in iodine[131^I]metuximab mAb group（P〈0.05）.Conclusion For PLC,the efficacy of Iodine[131 I]Metuximab Injection is superior to TACE in improving tumor regression rate,negative conversion rate of AFP and survival rate.

关 键 词：碘[131^I]美妥昔单抗 肝动脉化疗栓塞术 原发性肝癌 甲胎蛋白 

分 类 号：R735.7[医药卫生—肿瘤]